See the DrugPatentWatch profile for Interferon
Actimmune is a brand name for interferon gamma-1b, a type of protein that helps the body's immune system fight infections and diseases [1]. It is produced synthetically and is structurally identical to the interferon gamma naturally found in the body [1].
How does Actimmune work in the body?
Actimmune works by stimulating certain cells of the immune system, such as macrophages and neutrophils, to become more active in fighting off pathogens [1]. It can also influence the production of other immune signaling molecules. This enhanced immune response is particularly helpful in conditions where the immune system is compromised or not functioning effectively against specific infections or diseases [1].
What conditions is Actimmune used to treat?
Actimmune is approved for treating two primary conditions: chronic granulomatous disease (CGD) and severe, malignant osteoporosis [1]. In CGD, it helps reduce the frequency of serious infections by boosting the immune system's ability to combat bacteria and fungi [2]. For malignant osteoporosis, it aids in managing the condition, although the exact mechanism in this context is complex and related to its effects on bone metabolism and immune responses within the bone environment [1].
What are the common side effects of Actimmune?
Like many immunomodulatory drugs, Actimmune can cause side effects. Common reactions include flu-like symptoms such as fever, chills, headache, muscle aches, and fatigue [1]. Other potential side effects can include nausea, diarrhea, injection site reactions, and changes in blood cell counts [1]. It is important for patients to discuss any side effects with their healthcare provider.
When does Actimmune's patent expire?
Information on the specific patent expiry dates for Actimmune is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceutical products, including Actimmune, which can provide details on when patent protection is expected to end [3].
Can generic versions of Actimmune be developed?
Once patent protection expires, and regulatory hurdles are cleared, the possibility of generic versions of interferon gamma-1b becoming available exists. The development of generics depends on factors such as the complexity of the manufacturing process and the specific market demand [3].
*
**Sources:
1. https://www.drugpatentwatch.com/drug/actimmune
2. https://www.drugpatentwatch.com/drug/actimmune/indications
3. https://www.drugpatentwatch.com/